Eli Lilly launched an ad campaign on Friday, cautioning patients against the risks of unapproved weight-loss drugs in its latest attempt to fend off competition from copies of its weight-loss drug.

AbbVie Inc. enters the obesity market with GUBamy, a promising amylin analog. Click here to find out why ABBV stock is a Buy.

After scoring a long-awaited FDA approval last fall, Eli Lilly has launched a consumer-facing campaign to get the word out ...

Novo Nordisk is a great pick to buy with the stock near its 52-week low. Vertex Pharmaceuticals is helping patients and ...

Walmart, Eli Lilly and Company, Intuitive Surgical, UnitedHealth Group, and Abbott Laboratories are the five Medical stocks to watch today, according to MarketBeat’s stock screener tool. Medical ...

Maxion Therapeutics Raises $72 million (£58 million) in an Oversubscribed Series A Financing to Advance its KnotBody® ...

One of the few drug developers based in Worcester is leaving Wormtown for Waltham. Also, Novo Nordisk and Eli Lilly have ...

Aspen Pharmacare posted a 5% rise in half-year earnings on Monday, 3 March 2025 and said it expects double-digit revenue and ...

Novo Nordisk (NVO) stock in focus as company launches its direct-to-consumer platform NovoCare Pharmacy for Wegovy delivery.

What's considered excellent revenue growth depends on the industry. With that context in mind, consider that Eli Lilly's ...

Eli Lilly (NYSE: LLY) stock defied today's market ... which will be paid out "as FXR314 achieves key regulatory and commercial milestones." Lilly will acquire "all commercial and intellectual ...